OxAG is currently the only company in Central Europe with a high-throughput MDR antimicrobial screening platform using C. elegans. The C-biotic platform allows OxAG to test activity, toxicology and mode of action in one system The C-biotic platform is particularly suited to identify bacteriostatic compounds, and to quickly reveal antibiotic activity of compounds that were not previously considered antibiotic candidates. In addition to the antibiotic screening, we have established C. elegans models for age associated neurodegenerative disorders (Alzheimer´s disease, Parkinson´s diseases, Huntington disease and amyotrophic lateral sclerosis).